Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer C Samp

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pharmacotherapy|May 15, 2012
Retracted publications in the drug literatureJennifer C Samp, Glen T Schumock, A Simon Pickard
Clinics and Research in Hepatology and Gastroenterology|December 17, 2014
Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in FranceJennifer C Samp, Richard Perry, James Piercy, et al.
Pharmacotherapy|November 12, 2013
Economic evaluation of the impact of medication errors reported by U.S. clinical pharmacistsJennifer C Samp, Daniel R Touchette, Jacqueline S Marinac, et al.
Cancer Biology & Therapy|March 28, 2018
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapiesAnthony R Mato, Jennifer C Samp, Geneviève Gauthier, et al.
Journal of Medical Economics|May 13, 2016
Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infectionScott J Johnson, Hélène Parisé, Suchin Virabhak, et al.
Journal of Medical Economics|June 28, 2016
Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in JapanSuchin Virabhak, Kikuo Yasui, Kiyotaka Yamazaki, et al.
The Annals of Pharmacotherapy|July 6, 2017
Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β<sub>2</sub>-Agonist Combined With a Long-Acting Muscarinic or Inhaled CorticosteroidJennifer C Samp, Min J Joo, Glen T Schumock, et al.
Pharmacotherapy|February 23, 2017
Comparative Effectiveness of Long-Acting Beta<sub>2</sub> -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary DiseaseJennifer C Samp, Min J Joo, Glen T Schumock, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Predicting Acute Exacerbations in Chronic Obstructive Pulmonary DiseaseJennifer C Samp, Min J Joo, Glen T Schumock, et al.
Journal of Managed Care & Specialty Pharmacy|August 27, 2015
Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive DisordersValery Walker, Haridarshan Patel, Jonathan L Kurlander, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmacotherapy|May 15, 2012
Retracted publications in the drug literatureJennifer C Samp, Glen T Schumock, A Simon Pickard
Clinics and Research in Hepatology and Gastroenterology|December 17, 2014
Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in FranceJennifer C Samp, Richard Perry, James Piercy, et al.
Pharmacotherapy|November 12, 2013
Economic evaluation of the impact of medication errors reported by U.S. clinical pharmacistsJennifer C Samp, Daniel R Touchette, Jacqueline S Marinac, et al.
Cancer Biology & Therapy|March 28, 2018
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapiesAnthony R Mato, Jennifer C Samp, Geneviève Gauthier, et al.
Journal of Medical Economics|May 13, 2016
Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infectionScott J Johnson, Hélène Parisé, Suchin Virabhak, et al.
Journal of Medical Economics|June 28, 2016
Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in JapanSuchin Virabhak, Kikuo Yasui, Kiyotaka Yamazaki, et al.
The Annals of Pharmacotherapy|July 6, 2017
Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β<sub>2</sub>-Agonist Combined With a Long-Acting Muscarinic or Inhaled CorticosteroidJennifer C Samp, Min J Joo, Glen T Schumock, et al.
Pharmacotherapy|February 23, 2017
Comparative Effectiveness of Long-Acting Beta<sub>2</sub> -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary DiseaseJennifer C Samp, Min J Joo, Glen T Schumock, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Predicting Acute Exacerbations in Chronic Obstructive Pulmonary DiseaseJennifer C Samp, Min J Joo, Glen T Schumock, et al.
Journal of Managed Care & Specialty Pharmacy|August 27, 2015
Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive DisordersValery Walker, Haridarshan Patel, Jonathan L Kurlander, et al.
Pageof 2